HAVE YOUR SAY: Submit your letter to us, and we will hand deliver them when we travel to Canberra on Monday 5th September 2022.
31
Jul
20
Jun
The PBAC recommends removing restrictions to make it easier for ALL ITP Patients to access TPORAs.
11
Oct
Leading ITP clinicians come together and deliver consensus guidelines for the treatment of (ITP) in adult patients.
03
Nov
ITP Australia delivers a number of recommendations to improve treatment access for patients living with Immune Thrombocytopenia.
28
Feb
Delivered in February 2020, the National Strategic Action Plan is the first national and coordinated plan to help deliver better outcomes for more than the estimated 2 million Australians living with a rare disease.
10
Jan
Included in the following article is the recently published and updated International Consensus Report for the investigation, treatment and management of Immune Thrombocytopenia (ITP) in all patients.
10
Dec
Through the ITP World Impact Survey (I-WISh), which was a collaborative global survey completed by over 1,400 ITP patients and 480 health professionals, we review the perceptions between physicians and patients and identify that fatigue is under-recognised as a symptom and its impact on a patients Quality of life (QoL).
20
Nov
The ITP Impact Survey (I-WISh) is a collaborative investigation among global ITP experts, patient support groups and Novartis Pharmaceuticals Corporation.
31
Oct
05
Jul
The interim results for the I-WISh survey undertaken by Novartis, which collaborated with 480 health care providers across 13 countries, found that a high percentage of patients with Immune Thrombocytopenia experienced negative impacts to their quality of life due to the immune disease.